DIEMBERGER, IGOR
 Distribuzione geografica
Continente #
NA - Nord America 12.520
AS - Asia 11.960
EU - Europa 11.005
SA - Sud America 837
AF - Africa 710
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 9
Totale 37.063
Nazione #
US - Stati Uniti d'America 12.407
SG - Singapore 3.766
CN - Cina 3.202
VN - Vietnam 2.594
GB - Regno Unito 2.405
IT - Italia 2.157
DE - Germania 1.734
NL - Olanda 925
HK - Hong Kong 885
SE - Svezia 829
RU - Federazione Russa 663
IN - India 654
UA - Ucraina 651
BR - Brasile 610
FR - Francia 456
KR - Corea 365
IE - Irlanda 361
CI - Costa d'Avorio 254
EE - Estonia 198
ZA - Sudafrica 181
JP - Giappone 177
FI - Finlandia 169
AR - Argentina 115
TG - Togo 112
BG - Bulgaria 99
CH - Svizzera 84
SC - Seychelles 80
JO - Giordania 76
ID - Indonesia 73
AT - Austria 65
CA - Canada 55
PL - Polonia 45
BD - Bangladesh 40
MX - Messico 38
BE - Belgio 37
NG - Nigeria 36
EC - Ecuador 33
IR - Iran 30
GR - Grecia 24
ES - Italia 22
AU - Australia 20
CL - Cile 19
IQ - Iraq 18
PY - Paraguay 18
CO - Colombia 17
RO - Romania 17
TR - Turchia 14
EG - Egitto 12
PK - Pakistan 12
LT - Lituania 9
PE - Perù 9
UY - Uruguay 9
MA - Marocco 8
DO - Repubblica Dominicana 7
LB - Libano 7
TN - Tunisia 7
UZ - Uzbekistan 7
VE - Venezuela 7
EU - Europa 6
MY - Malesia 6
DK - Danimarca 5
IL - Israele 5
KE - Kenya 5
RS - Serbia 5
SK - Slovacchia (Repubblica Slovacca) 5
AL - Albania 4
AZ - Azerbaigian 4
HR - Croazia 4
HU - Ungheria 4
NO - Norvegia 4
PT - Portogallo 4
SA - Arabia Saudita 4
TH - Thailandia 4
AE - Emirati Arabi Uniti 3
BY - Bielorussia 3
CZ - Repubblica Ceca 3
HN - Honduras 3
KZ - Kazakistan 3
LU - Lussemburgo 3
SM - San Marino 3
SN - Senegal 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
CR - Costa Rica 2
DZ - Algeria 2
LK - Sri Lanka 2
SI - Slovenia 2
VA - Santa Sede (Città del Vaticano) 2
AD - Andorra 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BF - Burkina Faso 1
BW - Botswana 1
BZ - Belize 1
CG - Congo 1
CM - Camerun 1
CY - Cipro 1
DM - Dominica 1
Totale 37.046
Città #
Singapore 2.526
Southend 2.107
Ashburn 1.392
Fairfield 1.363
Hong Kong 881
Hefei 859
Chandler 727
Santa Clara 680
Woodbridge 670
Kerkrade 652
Wilmington 622
Seattle 583
Princeton 563
Houston 551
Dong Ket 497
Ho Chi Minh City 471
Jacksonville 451
Cambridge 446
Beijing 397
Frankfurt am Main 388
Boardman 364
Dublin 361
Seoul 353
Hanoi 348
Ann Arbor 326
Abidjan 254
Bologna 235
Westminster 231
Nanjing 210
Padova 198
Los Angeles 188
Milan 175
Berlin 172
Tokyo 168
Dallas 146
Saint Petersburg 134
Rome 127
Jinan 126
Buffalo 121
Helsinki 120
New York 117
Lomé 112
Shenyang 111
Redondo Beach 105
Sofia 94
Medford 90
San Diego 89
Bremen 88
Bengaluru 84
Changsha 79
Mülheim 79
Turin 78
Amman 76
São Paulo 76
Munich 70
Nanchang 65
Hebei 64
Des Moines 62
Redmond 61
Bern 57
Mahé 57
Guangzhou 54
Haiphong 47
Jiaxing 47
Chicago 45
Nuremberg 45
Zhengzhou 45
Tianjin 44
Jakarta 41
Yubileyny 40
Da Nang 38
London 38
Olalla 38
Abeokuta 35
Hangzhou 35
Shanghai 35
Bari 34
Brussels 34
Ningbo 34
Biên Hòa 33
Dearborn 33
Naples 33
Falkenstein 32
Lappeenranta 32
Verona 31
Warsaw 30
Phoenix 29
Taizhou 29
Düsseldorf 28
Bühl 26
Brooklyn 25
Florence 25
Haikou 25
Ninh Bình 25
Norwalk 25
Vienna 25
Quận Bình Thạnh 24
Tongling 24
Falls Church 23
Toronto 22
Totale 24.205
Nome #
'Real-World' antithrombotic treatment in atrial fibrillation: The eorp-af pilot survey 1.246
Incremento dei valori di troponina T dopo impianto di pacemaker con elettrodi a fissaggio attivo e passivo. 1.027
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system 273
Delayed asymptomatic migration of an implantable cardioverter-defibrillator lead to the costophrenic angle. 267
Acute and chronic haemodynamic effects of biventricular pacing and of switching to different pacing modalities in heart failure patients 255
11C-mHED for PET / CT: principles of synthesis, methodology and first clinical applications 226
Actual pacemaker longevity: the benefit of stimulation by automatic capture verification. 222
Atrial fibrillation: it is better to be alone than in bad company! 217
P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion. 214
Fattori predittivi di rimodellamento cardiaco inverso del ventricolo sinistro in pazienti candidati a terapia di resincronizzazione cardiaca: il ruolo dell’eziologia. 209
Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry 208
Automated CO2 angiography: Injection pressure and volume settings 206
Atrial fibrillation and prediction of mortality by conventional clinical score systems according to the setting of care 198
AF burden is important - Fact or fiction? 195
Bridging the future of cardiac stimulation: physiologic or leadless pacing? 193
Arrhythmia discrimination by physician and defibrillator: importance of atrial channel. 189
A changing scenario in the clinical use of implantable defibrillators: the need for long-term data on lead performance. 187
From lead management to implanted patient management: indications to lead extraction in pacemaker and cardioverter-defibrillator systems 186
Balancing the risk of hemorrhage vs thromboembolism in patients with atrial fibrillation: how to navigate between Scylla and Charybdis? 185
Cardiac resynchronization therapy: variations in echo-guided optimized atrioventricular and interventricular delays during follow-up. 185
Asymptomatic Atrial Fibrillation: Clinical Correlates, Management, and Outcomes in the EORP-AF Pilot General Registry 183
Farmaci antiaritmici 182
Electrocardiographic remodeling during cardiac resynchronization therapy 182
Assessment of regional left ventricular function by radionuclide angiography in CRT patients. Proceedings 16th World Congress in Cardiac Electrophysiology and Cardiac Techniques. 175
A Randomized Study of Cardiac Resynchronization Therapy Defibrillator Versus Dual-Chamber Implantable Cardioverter-Defibrillator in Ischemic Cardiomyopathy With Narrow QRS: The NARROW-CRT Study 174
Battery drain in daily practice and medium-term projections on longevity of cardioverterdefibrillators: An analysis from a remote monitoring database 174
Biventricular ICDs and rhythm discrimination by analysis of QRS morphology: are there QRS changes associated with left ventricular reverse remodeling? Poster European Congress of Cardiology 2007 173
Atrial fibrillation ablation: beyond electro-mechanical matters 171
Exploring Microphone Technologies for Digital Auscultation Devices 165
Use of Diltiazem in Chronic Rate Control for Atrial Fibrillation: A Prospective Case-Control Study 165
Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System 165
Cardiac resynchronization therapy: a comparison among left ventricular bipolar, quadripolar and active fixation leads 165
How to truly value implantable cardioverter-defibrillators technology: Up-front cost or daily cost? 165
Acute primary purulent pericarditis in an adult patient with unknown X-linked agammaglobulinemia 163
Pharmacological cardioversion of atrial fibrillation : current management and treatment options. 162
Cardiac resynchronization therapy in persistent left superior vena cava: Can you do it two-leads-only? 161
A comparison among three different echocardiographic methods for Interventricular delay optimization. Poster European Congress of Cardiology 2008 161
Atrial fibrillation in heart failure patients undergoing resynchronization therapy: what decision making? Proceedings 16th World Congress in Cardiac Electrophysiology and Cardiac Techniques 160
Clinical implications of left superior vena cava persistence in candidates for pacemaker or cardioverter-defibrillator implantation 159
Drug-induced Kounis syndrome: A matter of pharmacovigilance 157
How, why, and when may atrial defibrillation find a specific role in implantable devices? A clinical viewpoint. 156
Role of 18F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: A prospective study 155
Electrocardiographic Eligibility for Subcutaneous Implantable Cardioverter Defibrillator: Evaluation during Bicycle Exercise 155
Contribution of PET imaging to mortality risk stratification in candidates to lead extraction for pacemaker or defibrillator infection: a prospective single center study 154
Wireless Endocardial Atrial (and Ventricular) Sensing with no Implanted Power Source: a Proposal 153
Biventricular Pacing: Electrocardiographic Versus Structural Remodeling 152
Resincronizzazione cardiaca con pacing biventricolare o ventricolare sinistro: effetti a medio termine su funzione sistolica e sincronia ventricolare sinistra 151
Implantation of cardioverter-defibrillator: Effects on shoulder function. 151
Automatic management of atrial and ventricular stimulation in a contemporary unselected population of pacemaker recipients: the ESSENTIAL Registry 150
Analisi costi-benefici dell’impianto di cardioverter-defibrillatore 149
Effects of cardiac resynchronization therapy on diastolic function: evaluation by radionuclide angiography. 149
Management of Phrenic Stimulation in CRT Patients over the Long Term: Still an Unmet Need ? 148
The "Subtle" connection between development of cardiac implantable electrical device infection and survival after complete system removal: An observational prospective multicenter study 148
Cardiac resynchronization therapy in clinical practice: Need for electrical, mechanical, clinical and logistic synchronization. 148
Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction 148
Troponin I rise after pacemaker implantation at the time of "universal definition of myocardial infarction" 147
Cardioversione atriale interna: valutazione prospettica dei fattori determinanti il dolore indotto dallo shock. 146
'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: The EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry 146
Clinical management of atrial fibrillation: need for a comprehensive patient-centered approach. 145
Cardiac resynchronization therapy: effects on left and right ventricular ejection fraction during exercise. 145
Atrial fibrillation and heart failure: does one epidemic feed he other? 145
Comparison Between a Single-Lead ECG Garment Device and a Holter Monitor: A Signal Quality Assessment 144
Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: Time courses and prediction of response. 144
Valutazione angiocardioscintigrafica dei pazienti sottoposti aterapia di resincronizzazione cardiaca; esperienza del centro di Bologna. 143
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis 142
Outcomes with dronedarone in atrial fibrillation: What differences between real-world practice and trials? A meta-analysis and meta-regression analysis 142
Is ventricular sensing always right, when it is left? 141
Repolarization effects of multiple-cycle chemotherapy and predictors of QTc prolongation: A prospective female cohort study on >2000 ECGs 141
Clinical management of electromagnetic interferences in patients with pacemakers and implantable cardioverter-defibrillators: review of the literature and focus on magnetic resonance conditional devices 138
Cardiac resynchronization therapy and cardiac sympathetic function. 138
From lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction 137
Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes 137
Predictors of long-term survival free from relapses after extraction of infected CIED. 137
Algoritmi diagnostici nei defibrillatori mono e bicamerali: analisi delle capacità di discriminazione delle aritmie sopraventricolari e ventricolari. 137
Outcome of cardioverter-defibrillator implant in patients with arrhythmogenic right ventricular cardiomyopathy. 137
Association between clinical risk scores and mortality in atrial fibrillation: Systematic review and network meta-regression of 669,000 patients 136
Predictors of nonsimultaneous interventricular delay at cardiac resynchronization therapy optimization 136
Recurrence of pericarditis after influenza vaccination: a case report and review of the literature 136
Self-reported physical activity and major adverse events in patients with atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry 136
Phrenic stimulation: a challenge for cardiac resynchronization therapy 135
Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project. 135
Long-Term Atrioventricular Block Following Valve Surgery: Electrocardiographic and Surgical Predictors 134
Effetti emodinamici del pacing biventricolare a distanza di un anno dall'impianto 133
Less is more: Can we achieve cardiac resynchronization with 2 leads only? 133
Expenditure and value for money: the challenge of implantable cardioverter defibrillators 132
Holter ECG for pacemaker/defibrillator carriers: What is its role in the era of remote monitoring? 131
The effects of gender on electrical therapies for the heart: physiology, epidemiology, and access to therapies 131
Biventricular pacing in heart failure: what relationship between electrocardiographic and structural remodeling? 131
Atrial fibrillation: Adverse effects of "pill-in-the-pocket" treatment and propafenone-carvedilol interaction. 131
Role of drugs and devices in patients at risk of sudden cardiac death. 131
The QRS interval in patients treated with resynchronization therapy: which value 130
Meta-analysis of clinical outcomes of electrical cardioversion and catheter ablation in patients with atrial fibrillation and chronic kidney disease 130
Electrical cardioversion for persistent atrial fibrillation or atrial flutter in clinical practice: predictors of long-term outcome. 129
Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death 128
La cardioversione elettrica nella pratica clinica:quali predittori di efficacia della procedura e di recidiva di fibrillazione/flutter atriale a lungo termine? 128
Cardiac resynchronization therapy and VV interval optimization: which relationship between QRS width and the results of echo-guided VV interval optimization? 128
Long-term RV threshold behavior by automated measurements: safety is the standpoint of pacemaker longevity! 128
Atrial fibrillation in patients with a dual defibrillator: characteristics of spontaneous and induced episodes and effect of ventricular tachyarrhythmia induction. 128
Telecardiology and remote monitoring of implanted electrical devices: the potential for fresh clinical care perspectives. 127
L'ottimizzazione degli intervalli AV e VV nei pazienti con device biventricolare: revisione della letteratura e contributo sperimentale 127
Totale 17.833
Categoria #
all - tutte 102.522
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.522


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.468 0 0 0 0 0 143 41 203 308 188 159 1.426
2021/20224.152 344 187 262 318 422 252 113 380 165 198 747 764
2022/20234.533 446 563 212 596 269 277 157 237 833 248 349 346
2023/20241.566 125 219 109 116 152 295 92 122 72 111 68 85
2024/20256.574 294 1.236 524 469 1.050 289 349 161 96 402 386 1.318
2025/20269.361 1.658 1.692 1.574 1.233 1.478 1.726 0 0 0 0 0 0
Totale 37.786